Fig. 1: Mutant IL-12 attenuates NK cell activation and toxicity. | Nature Communications

Fig. 1: Mutant IL-12 attenuates NK cell activation and toxicity.

From: Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses

Fig. 1

a, b MC38 tumor-bearing mice (n = 4/group) were intraperitoneally treated with PBS or 5 μg IL-12 on days 14 and 17. For NK cell depletion, mice were intraperitoneally injected with 400 μg αNK1.1 antibody one day before treatment and then once every 3 days for three times. a The body weight change curve of mice after treatment. b The IFN-γ level in serum 6 h after the second treatment. c NK cells were incubated with mIL12wt, mIL12mut1, or mIL12mut2 for 48 h. The IFN-γ in the supernatant was detected (n = 3). d–f MC38 tumor-bearing mice (n = 4/group) were intraperitoneally treated with PBS or 5 μg mIL12wt, mIL12mut1, or mIL12mut2 on days 14, 17, and 20. d The body weight change curve of mice after treatment. e The IFN-γ and f ALT in serum 24 h after the third treatment. All data are shown as mean ± SD from two to three independent experiments. The P value was determined by one-way (b, e, f) or two-way ANOVA (a, d).

Back to article page